# AMR Action Fund

> AMR Action Fund is a VC fund in Boston backing Biotechnology and Therapeutics. See 22 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Boston, United States
- Total investments: 22
- Last investment: Aug 2026
- Lead investor: 82%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/amr-action-fund
- X (Twitter): https://twitter.com/AMRActionFund
- Website: https://amractionfund.com/

AMR Action Fund is a VC fund in Boston focused on Biotechnology and Therapeutics. AMR Action Fund renders investment, healthcare, biotech, research and development, pharmaceutical, and antibiotic services. They invest in firms that are developing critical pathogen therapies and lobby for market reforms to transform how society values these lifesaving drugs. They aim to help launch two to four new antimicrobials over the nextdecade and build a sustainable investment environment.

## Contacts

5 contacts available for AMR Action Fund. Shizune tracks 2 team members at AMR Action Fund. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/amr-action-fund?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 12 | 55% |
| Therapeutics | 8 | 36% |
| Health Care | 7 | 32% |
| Medical | 6 | 27% |
| Pharmaceutical | 5 | 23% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 4 | 18% |
| Series C | 3 | 14% |
| Series A | 2 | 9% |
| Series E | 2 | 9% |
| Series H | 1 | 5% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 7 | 32% |
| United Kingdom | 2 | 9% |
| Spain | 1 | 5% |
| France | 1 | 5% |
| Israel | 1 | 5% |

6 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Henry Skinner | Chief Executive Officer | 18 | https://shizune.co/investors/profile/dr-henry-skinner |
| Sergei Petukhov | Managing Director | 0 | https://shizune.co/investors/profile/sergei-petukhov |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Vedanta Biosciences | Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing ofrationally-defined bacterial consortia in powder form, enabling physicians to access live bacteria drug to treat autoimmune and inflammatory diseases easily.It was founded in 2010 and is headquartered in Cambridge, Massachusetts. | $40M | Venture - Series Unknown | Aug 06, 2026 |  |
| Trellis Bioscience | Trellis Bioscience develops a technology platform for cellular informatics. The company's technology has applications in the discovery and production of therapeutic monoclonal antibodies. Its cell biology platform provides a direct readout at the single cell level for monitoring activity of diverse cell types and quantifying the impact ofpotential therapeutic interventions. The company is based in San Francisco, California. | $9M | Series C | Jul 16, 2026 |  |
| Trellis Bioscience | Trellis Bioscience develops a technology platform for cellular informatics. The company's technology has applications in the discovery and production of therapeutic monoclonal antibodies. Its cell biology platform provides a direct readout at the single cell level for monitoring activity of diverse cell types and quantifying the impact ofpotential therapeutic interventions. The company is based in San Francisco, California. | $9M | Series C | Jul 16, 2026 |  |
| Telum Therapeutics | Telum Therapeutics is a biotechnology company that develops new treatments for infectious diseases based on the use of lytic enzymes from bacteriophages. | $20.5M | Series A | Jul 01, 2026 |  |
| Centauri Therapeutics | Centauri Therapeutics is a UK-based biotechnology company focused on the discovery and development of novel molecules targeting life threatening diseases. The Alphamer technology is based on "programmable immunity" in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight theinfection. The molecules have two distinct parts: one end binds a cell-surface target on the pathogen using an aptamer whereas the other end presents specific epitopes that attach to the circulating antibodies. It has been demonstrated that Alphamers have the potential to redirect pre-existing antibodies to bacteria in a specific manner and trigger an immediate antibacterial immune response, so clearing the infection. Centauri Therapeutics’ strategy is to redirect naturally occurring antibodies to target disease. Centauri Therapeutics' unique Chemistry Platform provides a flexible scaffold to enable the synthesis of specific Alphamers. These are bifunctional molecules which present a selective cell binding moiety as well as an epitope that recruits pre-existing antibodies, resulting in cell killing. Centauri Therapeutics believes their technology is widely applicable in the treatment of life threatening infectious diseases. Companies with an interest in accessing Centauri’s Alphamer technology or with an interest in one of their current projects, are warmly encouraged to contact them to discuss partnering opportunities. In order to drive success in the important area of immuno-oncology, Centauri Therapeutics has established a joint venture, Avvinity Therapeutics, with Horizon Discovery in March 2016. Avvinity combines Centauri’s Alphamer Technology with the gene editing and oncology expertise of Horizon. In addition to Centauri Therapeutics' immuno-oncology joint venture, Centauri maintains a strong network of collaborators in the areas of aptamer selection, drug discovery, chemistry and immunology. | $8.1M | Series A | Feb 24, 2026 |  |
| Centauri Therapeutics | Centauri Therapeutics is a UK-based biotechnology company focused on the discovery and development of novel molecules targeting life threatening diseases. The Alphamer technology is based on "programmable immunity" in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight theinfection. The molecules have two distinct parts: one end binds a cell-surface target on the pathogen using an aptamer whereas the other end presents specific epitopes that attach to the circulating antibodies. It has been demonstrated that Alphamers have the potential to redirect pre-existing antibodies to bacteria in a specific manner and trigger an immediate antibacterial immune response, so clearing the infection. Centauri Therapeutics’ strategy is to redirect naturally occurring antibodies to target disease. Centauri Therapeutics' unique Chemistry Platform provides a flexible scaffold to enable the synthesis of specific Alphamers. These are bifunctional molecules which present a selective cell binding moiety as well as an epitope that recruits pre-existing antibodies, resulting in cell killing. Centauri Therapeutics believes their technology is widely applicable in the treatment of life threatening infectious diseases. Companies with an interest in accessing Centauri’s Alphamer technology or with an interest in one of their current projects, are warmly encouraged to contact them to discuss partnering opportunities. In order to drive success in the important area of immuno-oncology, Centauri Therapeutics has established a joint venture, Avvinity Therapeutics, with Horizon Discovery in March 2016. Avvinity combines Centauri’s Alphamer Technology with the gene editing and oncology expertise of Horizon. In addition to Centauri Therapeutics' immuno-oncology joint venture, Centauri maintains a strong network of collaborators in the areas of aptamer selection, drug discovery, chemistry and immunology. | $8.1M | Series A | Feb 24, 2026 |  |
| Peptilogics | Peptilogics is a clinical-stage biotechnology company that designs and develops novel peptide therapeutics. Through their computational platform, Peptilogics is radically altering drug discovery by not only uncovering new, previously unexplored chemical design space but also ensuring that each potential therapeutic is biologically viable andscalable to manufacture. Peptilogics' lead clinical-stage peptide therapeutic, PLG0206, is a novel, broad-spectrum anti-infective that has been granted FDA Orphan Drug Designation and Qualified Infectious Disease Product Designation for its initial focus on the treatment of prosthetic joint infections, an unmet medical need. | $78M | Series B | Oct 16, 2025 |  |
| TenNor Therapeutics | TenNor Therapeutics is a clinical stage, product development company with a sharp focus on unmet medical needs in the area of infectious diseases. The company possesses a dual-acting drug discovery platform with several innovative products in various stages of preclinical and clinical development. The company is developing new drugs for thetreatment of Helicobacter pylori infections, prosthetic joint infections, multidrug-resistant Gram-negative infections and some other common and serious infectious diseases. | $42.1M | Series E | Oct 16, 2024 |  |
| F2G | F2G is advancing its own patented compounds and technologies which will lead to the development of novel agents to treat serious fungal disease. The Company was founded on its proprietary genomics technology (MycoBank®) that identifies essential gene targets in fungi. Having received initial funding in 2002 the company then rapidly diversifiedinto chemistry-driven discovery. They have also assembled an experienced development capacity. | $100M | Series H | Sep 12, 2024 |  |
| Elion Therapeutics | Elion Therapeutics is a cutting-edge biotechnology business focused on treating life-threatening IFIs. Elion was built on the notion that mechanistic insights allow for focused optimization of natural goods. | $81M | Series B | Jun 17, 2024 |  |

10 of 22 investments shown.

## Co-investors
- [Abingworth](https://shizune.co/investors/profile/abingworth-management) — VC Fund, 3 deals together
- [Invivo Capital Partners](https://shizune.co/investors/profile/invivo-capital-partners) — VC Fund, 3 deals together
- [Deerfield Management](https://shizune.co/investors/profile/deerfield-management-4e45) — VC Fund, 2 deals together
- [Easton Capital](https://shizune.co/investors/profile/easton-capital) — VC Fund, 2 deals together
- [New Science Ventures](https://shizune.co/investors/profile/new-science-ventures) — VC Fund, 2 deals together
- [The Doctor Group](https://shizune.co/investors/profile/the-doctor-group) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does AMR Action Fund invest in?

AMR Action Fund invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Series B and Series C stage. Most of the 22 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact AMR Action Fund?

Public channels for AMR Action Fund include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at AMR Action Fund?

The team at AMR Action Fund includes Henry Skinner (Chief Executive Officer) and Sergei Petukhov (Managing Director). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co